SCHEMBL7233109

SCHEMBL7233109

O=C(Nc1cc(C(=O)Nc2cccc3cc(S(=O)(=O)O)ccc23)cc(C(=O)Nc2cccc3cc(S(=O)(=O)O)ccc23)c1)c1ccc(Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGF1 P05230 1/20 0.59
CASP6 P55212 2/20 0.57
TIMP3 P35625 2/20 0.52
TRPV1 Q8NER1 1/20 0.52
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
ADORA3 P0DMS8 1/20 0.47
ADORA2A P29274 1/20 0.47
ADORA2B P29275 1/20 0.47
ADORA1 P30542 1/20 0.47
CTDSP1 Q9GZU7 1/20 0.46
PTGES O14684 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
GAA P10253 1/20 0.45
KDR P35968 1/20 0.45
RHOA P61586 1/20 0.44
PABPC1 P11940 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7226724 0.92 FGF1 (0.62) FGF1CASP6TIMP3TRPV1MEN1
SCHEMBL7233931 0.91 CASP6 (0.57) FGF1CASP6TIMP3MEN1KMT2A
SCHEMBL7223574 0.90 FGF1 (0.60) FGF1CASP6TIMP3MEN1KMT2A
SCHEMBL7233377 0.90 CASP6 (0.60) FGF1CASP6TIMP3MEN1KMT2A
SCHEMBL7224703 0.89 CASP6 (0.55) FGF1CASP6TIMP3TRPV1MEN1
SCHEMBL7230621 0.89 CASP6 (0.60) FGF1CASP6TIMP3MEN1KMT2A
SCHEMBL7232290 0.89 FGF1 (0.59) FGF1CASP6TIMP3MEN1KMT2A
SCHEMBL7224438 0.89 PTGES (0.55) FGF1CASP6TIMP3MEN1KMT2A
SCHEMBL7222503 0.87 TIMP3 (0.58) FGF1CASP6TIMP3TRPV1MEN1
SCHEMBL6240628 0.87 CASP6 (0.72) FGF1CASP6TIMP3TRPV1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653321-B1 Stimulating kinase activity of insulin receptor; type II diabetes; hyperglycemia TELIK, INC. 2003-11-25 US disclosed